Genmab A/S (Genmab A/S) Short-Term Capital Lease Obligation : $13 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Genmab A/S Short-Term Capital Lease Obligation?

Genmab A/S's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $13 Mil.

Genmab A/S's quarterly Short-Term Capital Lease Obligation declined from Jun. 2023 ($12 Mil) to Sep. 2023 ($12 Mil) but then increased from Sep. 2023 ($12 Mil) to Dec. 2023 ($13 Mil).

Genmab A/S's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($9 Mil) to Dec. 2022 ($11 Mil) and increased from Dec. 2022 ($11 Mil) to Dec. 2023 ($13 Mil).

Genmab A/S Short-Term Capital Lease Obligation Historical Data

The historical data trend for Genmab A/S's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Short-Term Capital Lease Obligation Chart

Genmab A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

3.87

6.87

9.42

10.54

13.17

Genmab A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															10.54	12.80	11.93	11.88	13.17

Genmab A/S Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Genmab A/S Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (Genmab A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OTCPK:GNMSF) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany

Address

Kalvebod Brygge 43, Copenhagen, DNK, 1560

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.